Nuveen Asset Management Portfolio holdings
Nuveen Asset Management, founded in 1898 by John Nuveen and headquartered in Chicago, Illinois, is a leading global investment manager and subsidiary of TIAA, overseeing hundreds of billions in assets with a focus on fixed income, equities, and sustainable investing. Initially known for municipal bonds, Nuveen has expanded into a broad range of strategies, including mutual funds, ETFs, closed-end funds, and private capital solutions, serving institutional investors, financial advisors, and individuals. The firm emphasizes income-generating investments and ESG (environmental, social, governance) integration, leveraging its deep research capabilities and a century-long legacy in the bond market. With a strong presence in North America and growing international reach, Nuveen blends tradition with innovation to meet diverse client needs in the evolving investment landscape.
Top Buys
| 1 |
Kenvue
KVUE
|
+$503M |
| 2 |
Intel
INTC
|
+$390M |
| 3 |
Zoetis
ZTS
|
+$245M |
| 4 |
Philip Morris
PM
|
+$216M |
| 5 |
Honeywell
HON
|
+$198M |
Top Sells
| 1 |
PepsiCo
PEP
|
+$525M |
| 2 |
RTX Corp
RTX
|
+$357M |
| 3 |
Apple
AAPL
|
+$341M |
| 4 |
Union Pacific
UNP
|
+$292M |
| 5 |
Microsoft
MSFT
|
+$243M |
Sector Composition
| 1 | Technology | 26.55% |
| 2 | Healthcare | 12.07% |
| 3 | Financials | 11.17% |
| 4 | Consumer Discretionary | 10.62% |
| 5 | Industrials | 8.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2726
Biomea Fusion
BMEA
$120M
| $616K | ﹤0.01% |
44,787
-10,288
| -19% | -$142K |
|
|
NSTG
2727
DELISTED
NanoString Technologies, Inc.
NSTG
| $614K | ﹤0.01% |
356,742
+46,415
| +15% | +$79.8K |
|
2728
Savara
SVRA
$627M
| $613K | ﹤0.01% |
162,212
+17,877
| +12% | +$67.6K |
|
2729
PetMed Express
PETS
$58.3M
| $611K | ﹤0.01% |
59,567
-107
| -0.2% | -$1.1K |
|
2730
Fate Therapeutics
FATE
$110M
| $608K | ﹤0.01% |
286,950
-1,771
| -0.6% | -$3.76K |
|
2731
Lineage Cell Therapeutics
LCTX
$315M
| $608K | ﹤0.01% |
515,445
| – | – |
|
2732
Karyopharm Therapeutics
KPTI
$54.3M
| $606K | ﹤0.01% |
30,160
-742
| -2% | -$14.9K |
|
2733
Lands' End
LE
$467M
| $603K | ﹤0.01% |
80,696
| – | – |
|
2734
Harvard Bioscience
HBIO
$21.6M
| $602K | ﹤0.01% |
139,999
| – | – |
|
2735
Nautilus Biotechnolgy
NAUT
$94.8M
| $601K | ﹤0.01% |
190,312
-1,609
| -0.8% | -$5.08K |
|
2736
Empire Petroleum
EP
$139M
| $599K | ﹤0.01% |
62,162
| – | – |
|
2737
Terns Pharmaceuticals
TERN
$639M
| $597K | ﹤0.01% |
118,680
-57,458
| -33% | -$289K |
|
2738
Arbutus Biopharma
ABUS
$843M
| $593K | ﹤0.01% |
292,022
-1,701
| -0.6% | -$3.45K |
|
2739
Actinium Pharmaceuticals
ATNM
$51.8M
| $588K | ﹤0.01% |
99,346
| – | – |
|
|
GRTS
2740
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $587K | ﹤0.01% |
341,449
| – | – |
|
2741
KalVista Pharmaceuticals
KALV
$682M
| $587K | ﹤0.01% |
60,952
-831
| -1% | -$8K |
|
2742
EverCommerce
EVCM
$2.12B
| $587K | ﹤0.01% |
58,480
-706
| -1% | -$7.08K |
|
2743
KRONOS Worldwide
KRO
$717M
| $587K | ﹤0.01% |
75,684
-1,291
| -2% | -$10K |
|
2744
Mistras Group
MG
$300M
| $586K | ﹤0.01% |
107,537
| – | – |
|
2745
Olaplex Holdings
OLPX
$967M
| $585K | ﹤0.01% |
300,147
-4,957
| -2% | -$9.67K |
|
|
MCBC
2746
DELISTED
Macatawa Bank Corp
MCBC
| $584K | ﹤0.01% |
65,194
-848
| -1% | -$7.6K |
|
2747
Vuzix
VUZI
$172M
| $582K | ﹤0.01% |
160,290
-279
| -0.2% | -$1.01K |
|
2748
Noodles & Co
NDLS
$31.4M
| $580K | ﹤0.01% |
235,941
-5,456
| -2% | -$13.4K |
|
2749
CorMedix
CRMD
$865M
| $580K | ﹤0.01% |
156,825
-40,210
| -20% | -$149K |
|
|
INZY
2750
DELISTED
Inozyme Pharma
INZY
| $579K | ﹤0.01% |
137,749
| – | – |
|